



Essai Clinique

Généré le 03 mai 2024 à partir de

Titre	Étude pancanadienne de surveillance moléculaire du myélome multiple menée par l'Institut de recherche Terry Fox
Protocole ID	NCI M4
ClinicalTrials.gov ID	NCT03421132
Type(s) de cancer	Myélome
Phase	Autres
Stade	Myélome multiple
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL  SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	
Investigateur principal	Dr Chaim Shustik Dr Michael Sebag
Coordonnateur	Nancy Renouf 514-934-1934 poste 35718
Statut	Actif en recrutement
But étude	The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.
Critères d'éligibilité	• Ability to give informed consent • Diagnosed with active multiple myeloma • Consented to participation in Myeloma Canada Research Network (MCRN) database project • Previously untreated and eligible for autologous stem-cell transplantation (ASCT)
Critères d'exclusion	• Ineligible for ASCT • Does not consent to participate in MCRN database project